Related Experiment Video
Updated: Jan 26, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma
Shaan Dudani1, Marie-France Savard1, Daniel Y C Heng1
1Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Canada.
Abstract:
One of the major challenges of personalized oncology lies in identifying predictive biomarkers of response to therapy that are practical in the clinical setting. Although many new targeted and immune-based treatments have emerged in recent years as effective systemic therapy options in metastatic renal cell carcinoma (mRCC), optimizing the selection and sequencing of treatments for any individual patient with this disease remains a significant challenge. The CheckMate-214 trial demonstrated that the International mRCC Database Consortium risk model is an effective predictive biomarker in the first-line treatment of mRCC. To date this remains the only prospectively validated predictive biomarker in mRCC. A number of other promising biomarker candidates are under active investigation but require prospective validation before widespread clinical adoption. PATIENT SUMMARY: The International Metastatic Renal Cell Carcinoma Database Consortium risk model is currently the only validated tool that can help clinicians in determining which patients should receive sunitinib versus a combination of nivolumab and ipilimumab as a first treatment for metastatic renal cell carcinoma. Other tools are being actively investigated.
Insights
The International Metastatic Renal Cell Carcinoma Database Consortium risk model is the sole validated tool for guiding first-line treatment selection in metastatic renal cell carcinoma. This predictive biomarker aids in choosing between sunitinib and nivolumab/ipilimumab combinations.
Area of Science:
- Oncology
- Biomarker Discovery
- Clinical Trial Validation
Background:
- Personalized oncology faces challenges in identifying practical predictive biomarkers for therapy response.
- Metastatic renal cell carcinoma (mRCC) has seen new targeted and immune therapies, yet treatment selection and sequencing remain complex.
- Optimizing treatment strategies for individual mRCC patients requires robust predictive tools.
Purpose of the Study:
- To highlight the significance of the International mRCC Database Consortium risk model as a validated predictive biomarker in mRCC.
- To discuss the current landscape of predictive biomarker research in first-line mRCC treatment.
- To emphasize the need for prospective validation of emerging biomarker candidates.
Main Methods:
- Analysis of data from the CheckMate-214 trial.
- Evaluation of the International mRCC Database Consortium risk model's performance as a predictive biomarker.
- Review of existing literature on predictive biomarkers in mRCC.
Main Results:
- The International mRCC Database Consortium risk model was prospectively validated as an effective predictive biomarker in the first-line treatment of mRCC.
- This model is currently the only prospectively validated predictive biomarker available for mRCC.
- Several other potential biomarkers are under investigation but lack prospective validation.
Conclusions:
- The International mRCC Database Consortium risk model is crucial for guiding first-line therapy decisions in mRCC, differentiating between sunitinib and nivolumab/ipilimumab.
- Widespread clinical adoption of new biomarkers requires rigorous prospective validation.
- Continued research into novel predictive biomarkers is essential for advancing personalized oncology in mRCC.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
02:27Predicting Molecular Geometry
01:03Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
01:07End Point Prediction: Gran Plot
For potentiometric titration, the Gran plot is created by plotting...